Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Recruiting
Observational Study
Lung Cancer
Venous Thromboembolism
Arterial Thromboembolism
Immune Checkpoint Inhibitors (ICIs)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,400 (estimated)
- Sponsor
- Beijing Chao Yang Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are:
1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 years
* Histopathologically confirmed lung cancer diagnosis at enrollment
* Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor
* Signed informed consent form
Exclusion Criteria:
* Presence of two or more primary cancers
* Missing d…
Contacts